Advanced search

Filters

Capitalization

Sector

Select all

Add a keyword

Announcement Date

Since

Until

36 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	16/04	GL
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	27/03	GL
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03	GL
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	08/03	GL
Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	20/02	GL
Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	20/02	AQ
Transcript : Argenx SE - Special Call	20/12
Argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus	20/12	GL
Transcript : Argenx SE - Special Call	28/11
Argenx Shares Down After Vyvgart Study Misses Primary Endpoint	28/11	DJ
Argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia	28/11	GL
Argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia	28/11	AQ
Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions	01/11	GL
Argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions	01/11	AQ
Transcript : Argenx SE - Special Call	17/23/17
Argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	17/23/17	GL
Transcript : Argenx SE - Special Call	21/23/21
Argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis	21/23/21	GL
Argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy	20/23/20	GL
Argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting	18/23/18	GL
Argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting	18/23/18	AQ
Argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod	27/23/27	GL
Argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod	27/23/27	AQ
Argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia	10/22/10	AQ
Argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia	10/22/10	GL
Transcript : Argenx SE, Q1 2022 Earnings Call, May 05, 2022	05/22/05
Argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia	05/22/05	GL
Argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia	05/22/05	AQ
Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting	05/22/05	AQ
Transcript : Argenx SE, Q4 2021 Earnings Call, Mar 03, 2022	03/22/03
Transcript : argenx SE, Q3 2021 Earnings Call, Oct 28, 2021	28/21/28
Argenx SE, - argenx Reports Third Quarter 2021 Financial Results and Provides Business Update	28/21/28	PU
Argenx Reports Third Quarter 2021 Financial Results and Provides Business Update	28/21/28	AQ
New Head-to-Head Phase 3 Study Data Show Ponesimod Superiority Versus Aubagio® (teriflunomide) 14 mg in Adults with Relapsing Multiple Sclerosis (MS)	11/19/11	PR
Alzheimer’s Team Receives Highest Honors at Annual XPRIZE Visioneers Summit	19/17/19	BU
YourEncore : Joins Global Alzheimer's Platform; Jason Bork Appointed Project Management Lead	16/14/16	MW

No results for this search